for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Karyopharm Therapeutics Inc

KPTI.OQ

Latest Trade

10.06USD

Change

-0.67(-6.24%)

Volume

554,122

Today's Range

9.66

 - 

10.70

52 Week Range

3.93

 - 

18.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.73
Open
10.61
Volume
554,122
3M AVG Volume
57.14
Today's High
10.70
Today's Low
9.66
52 Week High
18.52
52 Week Low
3.93
Shares Out (MIL)
61.92
Market Cap (MIL)
664.41
Forward P/E
-3.08
Dividend (Yield %)
--

Next Event

Q3 2019 Karyopharm Therapeutics Inc Earnings Release

Latest Developments

More

Karyopharm Announces Publication Of Xpovio (Selinexor) Phase 2b Storm Study Results In The New England Journal Of Medicine

Karyopharm Posts Q2 Loss Per Share Of $0.71

Karyopharm Therapeutics - On July 2, Anand Varadan Resigned As Chief Commercial Officer, Effective July 5

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.

Industry

Biotechnology & Drugs

Contact Info

85 Wells Ave

+1.617.6580600

https://karyopharm.com/

Executive Leadership

Sharon Shacham

President, Chief Scientific Officer

Michael G. Kauffman

Co-Founder, Chief Executive Officer and Director

Michael P. Mason

Chief Financial Officer, Senior Vice President, Treasurer

Christopher B. Primiano

Executive Vice President, Chief Business Officer, General Counsel and Secretary

Perry Monaco

Senior Vice President of Sales

Key Stats

1.44 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.920

2017

-2.810

2018

-3.140

2019(E)

-3.483
Price To Earnings (TTM)
--
Price To Sales (TTM)
65.83
Price To Book (MRQ)
7.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
128.72
LT Debt To Equity (MRQ)
128.72
Return on Investment (TTM)
-101.35
Return on Equity (TTM)
-87.27

Latest News

Karyopharm Therapeutics prices blood cancer treatment after FDA approval

Karyopharm Therapeutics Inc on Wednesday set a list-price for its blood cancer treatment Xpovio at $22,000 per month, following accelerated approval from the U.S. Food and Drug Administration.

CORRECTED-UPDATE 1-U.S. FDA approves Karyopharm Therapeutics' blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer.

U.S. FDA approves Karyopharm Therapeutics' blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer.

BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

* KARYOPHARM REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

BRIEF-Karyopharm Therapeutics Says Offering Shares Of Common Stock With Aggregate Offering Price Of $125 Mln

* KARYOPHARM THERAPEUTICS INC SAYS OFFERING SHARES OF CO'S COMMON STOCK WITH AN AGGREGATE OFFERING PRICE OF $125 MILLION - SEC FILING Source text : (https://bit.ly/2w3kEIH) Further company coverage:

BRIEF-Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock

* KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma

* KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

BRIEF-Karyopharm's Selinexor Receives Fast Track Designation From FDA

* KARYOPHARM'S SELINEXOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80

* KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

BRIEF-Karyopharm Announces Agreement For Biogen To Acquire KPT-350

* KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS

BRIEF-Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock

* KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION

BRIEF-Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing

* Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing Source text: (http://bit.ly/2h9XeaC) Further company coverage:

BRIEF-Karyopharm Q3 loss per share $0.65

* Karyopharm reports third quarter 2017 financial results and highlights recent progress

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

BRIEF-Karyopharm reports positive data from ongoing cancer drug study

* Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma

BRIEF-Karyopharm appoints Michael Falvey as CFO, adds new clinical strategy

* Karyopharm appoints Michael Falvey as chief financial officer, adds new clinical strategy and human resources executives and reports inducement grant under NASDAQ listing rule 5635(c)(4)

BRIEF-Karyopharm presents selinexor, KPT-9274 clinical data

* Karyopharm announces presentation of selinexor and KPT-9274 clinical data at the European Society of Medical Oncology 2017 annual meeting

BRIEF-Karyopharm Therapeutics Q2 loss per share $0.64

* Karyopharm reports second quarter 2017 financial results and highlights recent progress

BRIEF-Karyopharm doses first patient in pivotal phase 3 boston study

* Karyopharm doses first patient in pivotal phase 3 boston study evaluating selinexor in patients with relapsed/refractory multiple myeloma

BRIEF-Karyopharm Q1 loss per share $0.71

* Karyopharm reports first quarter 2017 financial results and highlights recent progress

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up